Zhongfeng Ye, Srinivasa Reddy Bonam, Lindsay G A McKay, Jessica A Plante, Jordyn Walker, Yu Zhao, Changfeng Huang, Jinjin Chen, Chutian Xu, Yamin Li, Lihan Liu, Joseph Harmon, Shuliang Gao, Donghui Song, Zhibo Zhang, Kenneth S Plante, Anthony Griffiths, Jianzhu Chen, Haitao Hu, Qiaobing Xu
The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. Here, we developed two messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccines, TU88mCSA and ALCmCSA, using the ancestral SARS-CoV-2 spike sequence, optimized 5' and 3' untranslated regions (UTRs), and LNP combinations. Our data showed that these nanocomplexes effectively activate CD4+ and CD8+ T cell responses and humoral immune response and provide complete protection against WA1/2020, Omicron BA...
December 26, 2023: Proceedings of the National Academy of Sciences of the United States of America